CIBC Private Wealth Group
CRL icon

CIBC Private Wealth Group’s Charles River Laboratories CRL Stock Holding History

CIBC Private Wealth Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.06M Buy
10,330
+602
+6% +$109K ﹤0.01% 568
2025
Q3 		$1.52M Sell
9,728
-5,141
-35% -$816K ﹤0.01% 620
2025
Q2 		$2.26M Sell
14,869
-597
-4% -$79.6K ﹤0.01% 535
2025
Q1 		$1.91M Buy
15,466
+1,869
+14% +$313K ﹤0.01% 538
2024
Q4 		$2.56M Sell
13,597
-139,870
-91% -$26.9M ﹤0.01% 525
2024
Q3 		$30.2M Buy
153,467
+405
+0.3% +$84.2K 0.05% 234
2024
Q2 		$31M Buy
153,062
+4,418
+3% +$1M 0.06% 217
2024
Q1 		$39.9M Buy
148,644
+1,990
+1% +$475K 0.08% 194
2023
Q4 		$34.7M Buy
146,654
+262
+0.2% +$51.5K 0.07% 207
2023
Q3 		$28.7M Sell
146,392
-487
-0.3% -$100K 0.07% 220
2023
Q2 		$30.9M Buy
146,879
+44,053
+43% +$8.76M 0.07% 225
2023
Q1 		$20.8M Sell
102,826
-587
-0.6% -$133K 0.05% 246
2022
Q4 		$22M Sell
103,413
-59
-0.1% -$12.9K 0.07% 169
2022
Q3 		$20.4M Buy
103,472
+1,539
+2% +$332K 0.05% 225
2022
Q2 		$21.8M Sell
101,933
-1,544
-1% -$377K 0.06% 223
2022
Q1 		$29.4M Buy
103,477
+2,508
+2% +$773K 0.06% 207
2021
Q4 		$38M Buy
100,969
+1,800
+2% +$699K 0.08% 183
2021
Q3 		$40.9M Buy
99,169
+19,811
+25% +$8.23M 0.1% 161
2021
Q2 		$29.4M Sell
79,358
-2,038
-3% -$681K 0.07% 203
2021
Q1 		$23.6M Sell
81,396
-2,970
-4% -$826K 0.06% 223
2020
Q4 		$21.1M Sell
84,366
-918
-1% -$219K 0.06% 229
2020
Q3 		$19.3M Sell
85,284
-1,053
-1% -$219K 0.06% 207
2020
Q2 		$15.1M Buy
+86,337
New +$13.8M 0.07% 182
2020
Q1 		– Sell
-1,885
Closed -$288K – 863
2019
Q4 		$288K Hold
1,885
– – ﹤0.01% 801
2019
Q3 		$250K Hold
1,885
– – ﹤0.01% 817
2019
Q2 		$267K Hold
1,885
– – ﹤0.01% 836
2019
Q1 		$274K Hold
1,885
– – ﹤0.01% 835
2018
Q4 		$213K Hold
1,885
– – ﹤0.01% 833
2018
Q3 		$254K Hold
1,885
– – ﹤0.01% 889
2018
Q2 		$212K Buy
+1,885
New +$204K ﹤0.01% 910

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

CIBC Private Wealth Group's CRL Position: Q4 2025 in Review

CIBC Private Wealth Group increased its Charles River Laboratories (CRL) stake by 6.2% in Q4 2025, buying an estimated $109K and bringing the position to 10,330 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #568.

CIBC Private Wealth Group first reported a position in CRL in Q2 2018 and has held it in 30 quarters since. The position peaked at $40.9M in Q3 2021. 581 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • CIBC Private Wealth Group held 10,330 shares of Charles River Laboratories worth $2.06M as of Q4 2025.
  • CIBC Private Wealth Group bought 602 Charles River Laboratories shares in Q4 2025, an estimated $109K.
  • Charles River Laboratories made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #568 holding.
  • CIBC Private Wealth Group first reported a position in Charles River Laboratories in Q2 2018 and has held it in 30 quarters since.
  • CIBC Private Wealth Group's Charles River Laboratories position peaked at $40.9M in Q3 2021.
  • 581 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.